RecruitingPhase 1 / Phase 2NCT04086485
Oncology
Carcinoid Tumor
Also known as well-differentiated neuroendocrine tumor, NET, carcinoid NET, serotonin-secreting tumor
Carcinoid tumours are well-differentiated (grade 1–2) neuroendocrine neoplasms most commonly arising in the small intestine, appendix, rectum, and bronchus, characterised by expression of neuroendocrine markers (synaptophysin, chromogranin
ORPHA:100091 ↗Prevalence 2–5 in 100,000 (rising with improved detection)Onset Adult (median age 50s–60s); varies by primary siteSporadic; rarely MEN1-associated
18
studies recruiting now
as of 7 Sept 2026
236
studies registered in total
as of 7 Sept 2026
14
countries with a recruiting site
as of 7 Sept 2026
10 Sept 2025
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT00646022
Natural History of Familial Carcinoid Tumor
RecruitingPhase 3NCT07087054
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
RecruitingPhase 2NCT05263050
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
RecruitingPhase 1NCT07165132
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 18 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Carcinoid Tumor study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: NANETS Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Carcinoid Tumor
Carcinoid tumours are well-differentiated (grade 1–2) neuroendocrine neoplasms most commonly arising in the small intestine, appendix, rectum, and bronchus, characterised by expression of neuroendocrine markers (synaptophysin, chromogranin A) and, in functional tumours, excessive production of serotonin and other vasoactive peptides. The carcinoid syndrome — episodic flushing, diarrhoea, and bronchospasm — occurs when vasoactive mediators bypass hepatic metabolism, typically indicating hepatic metastases or a primary bronchial carcinoid with direct systemic venous drainage. Long-acting somatostatin analogues (octreotide LAR, lanreotide) are the cornerstone of symptom control and have demonstrated antiproliferative activity in midgut NETs.
Common clinical features
Carcinoid syndrome: episodic cutaneous flushing (often triggered by alcohol, stress, or food), profuse watery diarrhoea, and abdominal crampingBronchospasm and wheezing from bronchoconstrictor mediator releaseCarcinoid heart disease: right-sided endocardial fibrosis causing tricuspid and pulmonary valve abnormalities from chronic serotonin exposureAbdominal pain from primary intestinal tumour, mesenteric fibrosis, or intestinal obstructionPellagra-like dermatitis from tryptophan diversion to serotonin synthesis causing niacin deficiencyWeight loss and malnutrition from diarrhoea and malabsorptionIncidental finding of a pulmonary or intestinal mass on imaging
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
3 approved treatments and 16 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Telotristat Ethyl (Xermelo)Approved: Octreotide Acetate (Bynfezia pen)Approved: Interferon Alfa-2b (Intron a)
Phase 3Pasireotide (Signifor)
Phase 3Octreotide
Phase 2Patupilone
Phase 2Nintedanib (Nintedanib component of ofev)
Phase 2Nivolumab (Nivolumab bms)
Phase 2Quarfloxin
Phase 2Bevacizumab (Abevmy)
Phase 2Estradiol (Adgyn estro)
+ 8 more in development
Before you apply
Things trial teams commonly ask about for Carcinoid Tumor. Not eligibility rules; those are set by each study.
- Biochemical documentation with plasma chromogranin A and 24-hour urinary 5-HIAA (or plasma 5-HIAA) is required for most functional NET trials; ensure values are obtained while off proton pump inhibitors (which falsely elevate chromogranin A).
- Somatostatin receptor expression confirmed by 68Ga-DOTATATE PET-CT is required for PRRT (peptide receptor radionuclide therapy) trials and for somatostatin analogue-related protocols — recent functional imaging within the protocol-specified window is essential.
- Ki-67 proliferation index and WHO grade (G1: Ki-67 <3%, G2: 3–20%, G3: >20%) must be documented from the most recent biopsy as they determine eligibility for graded therapy protocols and may change over time with tumour progression.
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).